Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495857 | 1.00 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6484633 | 1.00 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6484641 | 1.00 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6482692 | 0.88 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6482696 | 0.88 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6492406 | 0.88 | TACR1 (1.00) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6482486 | 0.88 | TACR1 (0.78) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6481995 | 0.88 | TACR1 (0.78) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6492103 | 0.88 | TACR1 (0.78) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6492091 | 0.88 | TACR1 (0.78) | TACR1KCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | claimed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-04 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | TACR1 981/4885KCNH2 2151/4885SLC6A4 113/4885 |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | CNR2, CNR1, HRH2 | TACR1 389/4885KCNH2 211/4885SLC6A4 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.